

factsheet | Medicines for Europe Vision

Providing sustainable access to high quality medicines for all European patients

Patients

1



- **Patient** access to medicines significantly increases when generic, biosimilar and value added medicines enter the market.
- Our members portfolio covers 80% of therapy areas, and supplies the majority of all prescribed medicines in Europe.

Quality

2



- Generic, biosimilar and value added medicines are developed and manufactured according to **stringent EU regulatory requirements**.
- Our members advocate the enforcement of high quality standards around the world.

Value

3



- Generic, biosimilar and value added medicines deliver **better value** to patients and healthcare systems.
- Our members provide an invaluable service to patient health and support **sustainable healthcare systems**.

Sustainability

4



- Over **160,000 skilled, high value direct jobs** in over **350 sites in Europe** produce your essential medicines.
- Our member companies are innovating: **up to 17% of their turn-over is invested in R&D**.
- Our industries export to over 100 countries worldwide.

Partnership

5



- **Medicines for Europe** works in close collaboration with the EU Institutions, governments, patient groups, healthcare professionals and other stakeholders to enhance public health in Europe.

patients • quality • value • sustainability • partnership

Follow us on



Rue d'Arlon 50 - 1000 Brussels - Belgium
T: +32 (0)2 736 84 11 - F: +32 (0)2 736 74 38
www.medicinesforeurope.com